PandemiCam — our greatest chance yet to detect, monitor and beat COVID-19?
Joint venture between Spinview and VR Media Technology creates device that provides accurate and fast detection of infectious people with far greater clarity than any single parameter test available today.
If not the deadliest, the novel coronavirus (COVID-19) is certainly the most serious contagious disease to have crossed continents in modern times. One of the biggest challenges is screening en-masse for the detection of infectious individuals. Today’s current methods are rudimentary (measuring only temperature) or very expensive and time-consuming (swab test).
A joint venture between Spinview and VR Media Technology has created an effective weapon against coronavirus. Using a proven successful matrix of sensors, PandemiCam can identify a wide range of symptoms to indicate infection, in seconds. Once the device is installed, unlimited tests can be performed without having to rely on consumable materials. The device is able to operate en-masse and report to a central server for infection monitoring and tracking. Accuracy is much higher than with non-contact thermometers, as the system can scan thousands of measurements per second across an entire spectrum of sensors, including, but going well beyond, only temperature. COVID-19 is known to affect physiological parameters such as temperature, respiration, hydration, sweating, flushing and coughing. PandemiCam is a non-invasive multisensory device, which is designed to collect information from multiple sensors to ‘read’ the COVID-19 symptom parameters in every person it scans. PandemiCam combines the use of mathematics and artificial intelligence (AI) with pre-existing sensors into one revolutionary scanning unit enabling widespread screening with ease. The collected data is fused together by the system and feed through AI, to provide accurate and fast detection of infectious people with far greater clarity than any single parameter test available today. The complex scanning system can help authorities across the globe limit the spread of COVID-19, assisting in the management of precious healthcare resources in real-time. Where current single parameter tests such as temperature have to be measured individually, PandemiCam is able to screen groups of people and even scan at a distance for the safety necessitated by this particular disease. Against a city grid, PandemiCam allows for the real-time mapping of symptoms. Quick identification of hotspots allows for localised restrictions and resource allocations, reducing financial damage and human danger. Dr Katarina Gospic, Director of Neuroscience at Spinview, said: "Our invention can give real-time information about the general health status of a population. This is data can contribute to a healthier world. The more frequently we can screen for infection in the case of corona, the better we will be at limiting spread. Healthcare systems could be provided with the number of infectious people in real-time, which would enable them to plan resources. Screening is crucial to winning the battle against corona."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance